China Pharma is a drug manufacturers - specialty & generic business based in the US. China Pharma shares (CPHI) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $0.23 – an increase of 0.51% over the previous week. China Pharma employs 231 staff and has a trailing 12-month revenue of around $6.2 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.23 |
|---|---|
| 52-week range | $0.17 - $1.21 |
| 50-day moving average | $0.21 |
| 200-day moving average | $0.33 |
| Wall St. target price | $3.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.92 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.2345 from 2024-10-15
| 1 week (2024-10-09) | 0.51% |
|---|---|
| 1 month (2024-09-16) | 20.88% |
| 3 months (2024-07-16) | -12.40% |
| 6 months (2024-04-16) | -29.43% |
| 1 year (2023-10-16) | 67.50% |
|---|---|
| 2 years (2022-10-14) | 80.38% |
| 3 years (2021-10-15) | 0.55 |
| 5 years (2019-10-16) | 0.2556 |
| Revenue TTM | $6.2 million |
|---|---|
| Gross profit TTM | $349,270 |
| Return on assets TTM | -17.54% |
| Return on equity TTM | -74.89% |
| Profit margin | -70.49% |
| Book value | $0.43 |
| Market Capitalization | $4.1 million |
TTM: trailing 12 months
We're not expecting China Pharma to pay a dividend over the next 12 months.
China Pharma's shares were split on a 1:5 basis on 5 March 2024. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your China Pharma shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for China Pharma shares which in turn could have impacted China Pharma's share price.
Over the last 12 months, China Pharma's shares have ranged in value from as little as $0.17 up to $1.212. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while China Pharma's is 0.737. This would suggest that China Pharma's shares are less volatile than average (for this exchange).
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.